DSIP (Delta Sleep-Inducing Peptide): Clinical Guide for Prescribing Practices
DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring neuropeptide that promotes delta wave (deep) sleep and modulates neuroendocrine function. It has been studied for sleep quality improvement, stress reduction, and cortisol modulation. It is used in optimization and longevity clinics for patients with sleep architecture disruption.
Also Known As
How DSIP (Delta Sleep-Inducing Peptide) Works
DSIP modulates hypothalamic sleep-wake regulation by influencing glutamatergic and GABAergic signaling in the ventrolateral preoptic area and suprachiasmatic nucleus [1]. It promotes delta wave (slow-wave) sleep by modulating the firing patterns of thalamocortical neurons responsible for sleep spindle generation [3]. Additionally, DSIP suppresses ACTH and cortisol secretion through hypothalamic-pituitary axis modulation, contributing to stress reduction and facilitating sleep onset [2].
Clinical Evidence
Schoenenberger et al. originally isolated DSIP from rabbit cerebral venous blood during electrically induced sleep and demonstrated its ability to promote delta EEG activity in recipient animals [1]. Subsequent human studies showed modest improvements in sleep onset latency and slow-wave sleep duration in chronic insomnia patients, with Graf and Kastin reporting improved subjective sleep quality [2]. Research has also demonstrated cortisol-modulating effects and potential applications in alcohol and opioid withdrawal [4]. The evidence base remains limited by small sample sizes and dated study methodologies [3].
Clinical Uses
Patient Selection and Screening
Best candidates are patients with documented poor sleep architecture (confirmed by polysomnography or wearable sleep trackers), particularly those with reduced slow-wave sleep who have already optimized sleep hygiene [3]. Also appropriate for patients with elevated evening cortisol disrupting sleep onset [2], and those seeking alternatives to pharmaceutical hypnotics. Not appropriate for patients with untreated sleep apnea, primary psychiatric insomnia requiring behavioral therapy, or as first-line treatment before sleep hygiene optimization.
Dosing and Administration
Subcutaneous injection dosing ranges from 100 to 300 mcg administered 30 to 60 minutes before desired sleep onset [3]. Intranasal formulations are dosed at 100 to 200 mcg per nostril. Cyclical protocols (5 to 10 consecutive nights, followed by 5 to 7 nights off) are preferred to prevent tolerance development [2]. Starting at the lower dose range and titrating based on subjective sleep quality scores is recommended. Some clinicians combine DSIP with melatonin or magnesium for synergistic sleep architecture support.
Route: Subcutaneous injection, intranasal
Protocol notes: Administered via subcutaneous injection or intranasal spray, typically in the evening 30-60 minutes before desired sleep onset. Dosing protocols vary; cyclical use (5-10 days on, then break) is common in clinical practice.
Side Effects and Monitoring
Clinical Considerations
Practice Economics
Sleep optimization represents a large and growing addressable market, with DSIP offering a peptide-based solution distinct from pharmaceutical hypnotics [3]. Practices can position DSIP within full sleep programs that include testing, behavioral coaching, and longitudinal monitoring. The cyclical dosing model creates natural follow-up appointments and ongoing patient engagement without daily dependency concerns [2].
FDA Category Status
Compounding eligibility varies; verify current FDA status before prescribing
FDA bulk drug substance category determines compounding eligibility. Category designations are subject to change; always verify the current status before prescribing. This information is provided for clinical reference and does not constitute legal or regulatory advice.
Pharmacy Integrations
Prescribe DSIP (Delta Sleep-Inducing Peptide) through Karpa's integrated compounding pharmacy network with one-click ordering and direct-to-patient fulfillment.
Frequently Asked Questions
What is the evidence for DSIP improving sleep quality?
How does DSIP compare to pharmaceutical sleep aids?
References
- Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram-sleep-inducing peptide. Proc Natl Acad Sci USA. 1977;74(3):1282-6.
- Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): a review. Neurosci Biobehav Rev. 1984;8(1):83-93.
- Schneider-Helmert D, Schoenenberger GA. Effects of DSIP in man: multifunctional psychophysiological properties besides induction of natural sleep. Neuropsychobiology. 1983;9(4):197-206.
- Dick P et al. DSIP in the treatment of withdrawal syndromes from alcohol and opiates. Eur Neurol. 1984;23(5):369-74.
Related Peptides in Cognitive & Neurological
Disclaimer: This information is intended for licensed healthcare providers only and does not constitute medical, legal, or regulatory advice. Clinical decisions should be based on your professional judgment, current evidence, and applicable state and federal regulations. Always verify FDA category status and compounding eligibility before prescribing. Content is reviewed periodically but may not reflect the most recent regulatory changes.
Prescribe DSIP (Delta Sleep-Inducing Peptide) Through Karpa
Streamline your peptide prescribing workflow with integrated pharmacy ordering, patient tracking, and compliance documentation.
Prescribe DSIP (Delta Sleep-Inducing Peptide) Through Karpa